← Back to Search

Procedure

Optimal Medical Treatment with delayed revascularization for Coronary Artery Disease (PETREVASC Trial)

N/A
Waitlist Available
Led By K. Lance Gould, MD
Research Sponsored by The University of Texas Health Science Center, Houston
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline and day 105 +20 and day 365+30
Awards & highlights

PETREVASC Trial Summary

This trial is comparing the two most common treatments for stable ischemic heart disease: revascularization (surgery to improve blood flow to the heart) and Optimal Medical Treatment (a combination of drugs to improve symptoms and reduce risk). The goal is to see which treatment is better at improving severely reduced coronary flow capacity.

Eligible Conditions
  • Coronary Artery Disease

PETREVASC Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline and day 105 +20 and day 365+30
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline and day 105 +20 and day 365+30 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change from baseline in the % of left ventricle (LV) with Coronary Flow Capacity (CFC)blue.
Change from baseline in the % of left ventricle (LV) with Coronary Flow Capacity (CFC)green.
Secondary outcome measures
Change in % of LV with CFCblue.
Change in % of LV with CFCgreen.
Change in CFC histogram distribution.
+11 more

PETREVASC Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Optimal Medical Treatment with delayed revascularizationExperimental Treatment1 Intervention
OMT without revascularization for a minimum of approximately 105 days if clinically stable. At their first follow-up visit (Day 105±20), patients will be offered the option of continued medical treatment or elective revascularization consistent with informed patient preference and clinical judgement. Patients, in consultation with their physicians, may elect to undergo revascularization at any time thereafter and will be followed for one year after randomization. Follow-up visits will occur at Baseline, Day 105, and Day 365. At each visit, a rest-stress PET assessment will be performed, and adverse events related to study procedures and cardiac disease will be captured.
Group II: Urgent revascularization with Optimal Medical TherapyActive Control1 Intervention
Revascularization will be performed via either Percutaneous Coronary Intervention or Coronary Artery Bypass Graft, and the selection of the specific procedure will be at the discretion of the patient and their physician(s). Patients will be followed for one year after randomization. Follow-up visits will occur at Baseline, Day 105, and Day 365. At each visit, a rest-stress PET assessment will be performed, and adverse events related to study procedures and cardiac disease will be captured.

Find a Location

Who is running the clinical trial?

The University of Texas Health Science Center, HoustonLead Sponsor
904 Previous Clinical Trials
320,946 Total Patients Enrolled
7 Trials studying Coronary Artery Disease
7,895 Patients Enrolled for Coronary Artery Disease
K. Lance Gould, MDPrincipal InvestigatorUT Health Science Center Houston
1 Previous Clinical Trials
1,085 Total Patients Enrolled
1 Trials studying Coronary Artery Disease
1,085 Patients Enrolled for Coronary Artery Disease

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Early Revascularization in Stable Ischemic Heart Disease Using P.E.T. Imaging
K.Lance Gould 2021. "Early Revascularization in Stable Ischemic Heart Disease Using P.E.T. Imaging". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05018247.
~4 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top